Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
California-based āshibio, a privately-held biotech developing therapeutics for bone and connective tissue disorders, has exited stealth mode today with $40 million in seed and Series A financing. 21 June 2024
Biotechnology
US precision genetic medicines firm Sarepta Therapeutic saw its close up 5% and soar a further 36.5% to $168.55 in after-hours activity, as it revealed a welcome indication extension for its Duchenne muscular dystrophy (DMD) drug. 21 June 2024
Pharmaceutical
French vaccines major Sanofi and Biovac, a Cape Town-based biopharmaceutical company, have announced a partnership to produce inactivated polio vaccines in Africa. 20 June 2024
Pharmaceutical
Midsize Japanese drugmaker Otsuka Pharmaceuticals says it has concluded an expanded licensing agreement for hereditary angioedema (HAE) drug candidate donidalorsen with Ionis Pharmaceuticals to cover the development and sales area to the Asia-Pacific region, including Japan. 20 June 2024
Biotechnology
Chicago, USA-based biopharma giant AbbVie has picked up a new nod for Skyrizi (risankizumab-rzaa), for adults with moderately to severely active ulcerative colitis. 19 June 2024
Biotechnology
Third Rock incubated clinical-stage biotech Marea Therapeutics launched yesterday with $190 million in combined Series A and B financings. 19 June 2024
Pharmaceutical
US chemoproteomics start-up Belharra Therapeutics, has entered into a strategic collaboration with French pharma major Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases. 19 June 2024
Biotechnology
US liver disease focused biotech Mirum Pharmaceuticals (Nasdaq: MIRM) saw its shares leap 15.4% to $29.90 by close of trading on Monday, as it reported interim results from two Phase IIb studies evaluating volixibat. 18 June 2024
Biotechnology
Elion Therapeutics, a biotechnology company focusing on invasive fungal infections, has announced the successful closing of an $81 million series B funding round. 17 June 2024
Biotechnology
Boston, USA-based Vertex Pharmaceuticals has announced longer-term data for Casgevy (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). 17 June 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze